These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 14682271)

  • 1. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abacavir as initial therapy and as a once-daily drug.
    Sax PE
    AIDS Clin Care; 2003 Nov; 15(11):93-4. PubMed ID: 14682271
    [No Abstract]   [Full Text] [Related]  

  • 2. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Prognosis after triple-class failure.
    Currier J
    AIDS Clin Care; 2003 Nov; 15(11):95. PubMed ID: 14682274
    [No Abstract]   [Full Text] [Related]  

  • 3. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Didanosine intensification in NRTI-experienced patients.
    Currier J
    AIDS Clin Care; 2003 Nov; 15(11):96. PubMed ID: 14682278
    [No Abstract]   [Full Text] [Related]  

  • 4. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
    Feinberg J
    AIDS Clin Care; 2003 Nov; 15(11):94. PubMed ID: 14682272
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-HIV agents. Abacavir once or twice daily.
    TreatmentUpdate; 2005; 17(5):8. PubMed ID: 17219659
    [No Abstract]   [Full Text] [Related]  

  • 6. [Valuable combination partner. Great benefit for therapy naive patients].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-HIV agents. Abacavir--as good as AZT?
    TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiretroviral update from the Interscience Conference on Antimicrobial Agents and Chemotherapy.
    Newsline People AIDS Coalit N Y; 1998 Dec; ():16-8. PubMed ID: 11367083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Report from the 2008 joint ICAAC/IDSA meeting. More data on abacavir/3TC.
    Sax PE
    AIDS Clin Care; 2008 Dec; 20(12):104. PubMed ID: 19271334
    [No Abstract]   [Full Text] [Related]  

  • 10. Selected highlights from ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy).
    TreatmentUpdate; 2002 Jan; 14(1):5-10. PubMed ID: 12141238
    [No Abstract]   [Full Text] [Related]  

  • 11. Coming therapies: abacavir.
    Staszewski S
    Int J Clin Pract Suppl; 1999 Jun; 103():35-8. PubMed ID: 10622042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Single agent therapy for HIV infection?
    Currier J
    AIDS Clin Care; 2003 Nov; 15(11):96. PubMed ID: 14682276
    [No Abstract]   [Full Text] [Related]  

  • 13. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.
    Becker S; Feinberg J
    AIDS Clin Care; 2003 Sep; 15(9):81. PubMed ID: 14669727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highlights of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
    Prescott LM
    Body Posit; 2002 Dec; 15(7):16-20. PubMed ID: 14989207
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.
    Maitland D; Jackson A; Osorio J; Mandalia S; Gazzard BG; Moyle GJ;
    HIV Med; 2008 Oct; 9(8):667-72. PubMed ID: 18631255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily abacavir in place of twice-daily administration.
    Goedken AM; Herman RA
    Ann Pharmacother; 2005; 39(7-8):1302-8. PubMed ID: 15956231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). T-1249 for T-20 salvage.
    Feinberg J
    AIDS Clin Care; 2003 Nov; 15(11):95-6. PubMed ID: 14682275
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.
    Gallant JE
    Hopkins HIV Rep; 2003 Jul; 15(4):1-2. PubMed ID: 14696559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.